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Percutaneous needle biopsy
1-4 under image guidance have 
been increasingly used in the diagnostic work-up of focal hepatic 
lesions. In addition, percutaneous ethanol injection therapy 
(PEIT)
5 and radiofrequency ablation (RFA)
6 are useful in 
managing hepatocellular carcinomas (HCC).
A liver mass with an elevated serum α-fetoprotein (AFP) 
does not automatically indicate HCC. Moreover, AFP is an 
inadequate surveillance assay in high-risk groups. The 
diagnosis of HCC depends on radiological appearances and 
histologic examinations. In most cases, contrast-enhanced 
computed tomography (CT) and magnetic resonance imaging 
(MRI) is highly accurate for the diagnosis of malignant 
liver cancers.
4,7 Hence, they have led to a drastic decline in 
the requirement for liver biopsy of space-occupying lesions.
8
The European Association for the Study of the Liver 
(EASL) recommends needle biopsy of lesions ranging from 
10 to 20 mm in diameter to patients with cirrhosis, since 
detection sensitivities of small malignant liver tumors (<2 
cm) in cirrhotic liver are less than 13-67%.
7,9 Furthermore, 
false positive results for HCC were reported as 7 % in liver 
transplantation (LT) recipients in the USA.
10 
The sensitivity of fine needle aspiration biopsy (FNA) of 
liver lesions reported range from 67 to 100%, the 
specificity 80 to 100%,
11 and the accuracy 91%.
11,12 Image 
guided percutaneous needle biopsies are generally a safe and 
highly effective tool for diagnosing liver tumors. Major 
complication rates and associated mortality rates by liver 
biopsy are 0.05-0.18% and 0.006-0.031%, respectively. Major 
complication rates and mortality rates of PEIT and RFA are 
less than 2% and up to 0.1%, respectively.
13,14
The biggest shortcoming of percutaneous biopsy is the 
potential risk of implantation of malignant cells into the 
needle tract. The incidence of needle tract implantation 
(NTI) of HCC has recently increased from 0.003-0.009% to 
1-5%.
2,15-18 The increased survival in patients with HCC may 
be one of the reasons for the high incidence reported in 
recent publications. Moreover, as the use of percutaneous 
interventional procedure becomes more popular, NTI of 
HCC is predicted to increase. In systematic review, the 
incidence of NTI following biopsy of HCC is 2.7% overall, 
or 0.9% per year.
3 Although the use of ethanol was thought 
to prevent NTI after PEIT,
19 the frequency of NTI is yet 
between 0.2-1.4%.
20 Llovet et al
21 reported a high rate 
(12.5%) of NTI after RFA, but later studies reported 
substantially lower rates.
1,6 This discrepancy is thought to 
have occurred due to the small number of patients and 
percutaneous biopsy before RFA in this study.
The following risk factors affect the chances of NTI
1; (1) 
the superficial or subcapsular location of the tumor,
2 (2) 
more number of needle passes
13,15 and the frequency of 
repositioning the needles (3) larger needle bore,
16 (4) the use 
of an end-cutting needle,
2,13,16 (5) the absence of or a too thin 
layer surrounding normal liver parenchyma along the needle 
tract,
13,15 (6) high-grade (moderate or poor) differentiated 
HCC,
2,13,20,21 (7) high serum AFP level,
21 (8) tumor larger 
than 2 cm, (9) biopsy before RFA,
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immunosuppression.
19 Maturen et al
22 suggested that a 
biopsy needle within an introducer could prevent needle 
tract seeding. In this method, the introducer stayed in place 
while multiple passes with the biopsy needle were made.
22 
Despite the usage of small caliber needles, PEIT may 
increase the risk of NTI compared to biopsy alone due to 
their multiple needle punctures and their stay in liver over an 
extended period.
20 Therefore, larger volumes of ethanol 
during needle placement for PEIT may minimize the risk of 
NTI because of the sterilizing effect of alcohol along the 
needle tract and fewer needle punctures.
19 Routine ablation 
of the needle tract during RFA and the use of an internally 
cooled electrode may also decrease the incidence of 
NTI.
1,2,21 Patients with small or well-differentiated HCC are 
expected to have a longer life span than those with large or 
poorly differentiated HCC.
15 Since the chance of detection 
of NTI is higher in the former,
1,15,16 ablation should also be 
considered for both the lesion and the needle tract in cases of 
biopsy from a small liver nodule.
Helical CT is the preferred imaging technique to 
demonstrate NTI.
2,15 The implanted tumors may show 
hyper-attenuation on the arterial phase. Thereafter, they 
show high to iso-attenuation on portal and equilibrium phase. 
The cause of the difference in the enhancement pattern 
between implanted tumors and HCC in the liver during the 
equilibrium phase is that the implanted tumor tissue is 
supplied only by the systemic arteries, unlike liver.
2
NTI can be treated with local excision with clear margins 
and/or ablation, embolization, or local radiotherapy.
15-17,19,20,22 
Surgical resection offers the best chance to eradicate the 
implanted tumors, and the seeding did not adversely affect 
patient survival with the lesion being treated successfully by 
resection and local ablation.
2,3,12,15-18,23 
The size of the tumor implant and extrahepatic dissemi-
nation of the implanted tumor can be thought to affect the 
outcome after resection.
23 However, the prognosis of HCC is 
usually dependent on liver function and the characteristics 
of intrahepatic lesions, not on the severity of metastatic 
lesions.
24 Therefore NTI itself rarely affects patient 
survival.
2,12,15-17,19,20,22
A study of Ahn et al
25 reported that incidence of NTI after 
percutaneous biopsy or PEIT is similar to the previous 
study,
26 and that percutaneous transhepatic biliary drainage 
(PTBD) can also induce NTI. Several treatment modalities 
are recommended for NTI of HCC and their results are 
known to be acceptable. However, in this study, even though 
the prognosis of HCC is usually independent from the 
degree of metastasis, one fourth of the patients recurred after 
surgical excision and only method of excision for implanted 
nodules was significantly associated with recurrence. Thereby, 
when NTI is detected, en bloc wide excision of implanted 
tumor appears to be a preferable option. 
Currently, LT has been proved to be an effective treatment 
option for HCC. Percutaneous procedure, including needle 
biopsy, PEIT or RFA in those patients would have a poor 
long term outcome of successful LT, because it turns a 
potentially curative lesion into an untreatable situation due 
to extrahepatic tumor dissemination along the needle track.
23 
Thus, some investigators emphasize that percutaneous 
interventional procedures are generally contraindicated and 
these procedures should be undertaken only in specialized 
liver transplant centers for selected cases of HCC. 
In conclusion, although uncommon, NTI after needle biopsy 
for HCC can occur with an incident that is not negligible. In 
order to avoid NTI, percutaneous biopsy should only be 
considered in cases when imaging results are ambiguous, or 
pathologic confirmation is necessary before nonsurgical 
treatments, such as transcatheter arterial chemoembolization 
(TACE), PEIT, RFA, or chemotherapy.
17,23 Since needle 
tract seeding may present after percutaneous interventional 
procedure and even after RFA, attention must be paid to the 
needle tract during extended follow-up.
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